ONCT – oncternal therapeutics, inc. (US:NASDAQ)

News

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com